EJNMMI radiopharmacy and chemistry

Keyphrases

Publications

volume 9, number 1, 2024

Panagiotis Kanellopoulos, Adam Mattsson, Ayman Abouzayed, Karim Obeid, Berthold A Nock, Vladimir Tolmachev, Theodosia Maina, Anna Orlova
Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Steve S Huang, Frank P DiFilippo, Daniel J Lindner, Warren D Heston
A novel PSMA-targeting tracer with highly negatively charged linker demonstrates decreased salivary gland uptake in mice compared to [ 68 Ga]Ga-PSMA-11. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Lei Wang, Hsiou-Ting Kuo, Zhengxing Zhang, Chengcheng Zhang, Chao-Cheng Chen, Devon Chapple, Ryan Wilson, Nadine Colpo, null François Bénard, Kuo-Shyan Lin
Unnatural amino acid substitutions to improve in vivo stability and tumor uptake of 68 Ga-labeled GRPR-targeted TacBOMB2 derivatives for cancer imaging with positron emission tomography. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Pyry Dillemuth, Tuomas Karskela, Abiodun Ayo, Jesse Ponkamo, Jonne Kunnas, Johan Rajander, Olli Tynninen, Anne Roivainen, Pirjo Laakkonen, Anu J Airaksinen, Xiang-Guo Li
Radiosynthesis, structural identification and in vitro tissue binding study of [ 18 F]FNA-S-ACooP, a novel radiopeptide for targeted PET imaging of fatty acid binding protein 3. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Xiaoqun Tang, Shengji Lv, Zhaobiao Mou, Xia Liu, Zijing Li
Cu(II)-Mediated direct 18 F-dehydrofluorination of phosphine oxides in high molar activity. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Panagiotis Kanellopoulos, Adam Mattsson, Ayman Abouzayed, Karim Obeid, Berthold A Nock, Vladimir Tolmachev, Theodosia Maina, Anna Orlova
Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Aruna Korde, Marianne Patt, Svetlana V Selivanova, Andrew M Scott, Rolf Hesselmann, Oliver Kiss, Natesan Ramamoorthy, Sergio Todde, Sietske M Rubow, Luther Gwaza, Serge Lyashchenko, Jan Andersson, Brian Hockley, Ravindra Kaslival, Clemens Decristoforo
Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Toshimitsu Okamura, Tatsuya Kikuchi, Masanao Ogawa, Ming-Rong Zhang
Improved synthesis of 6-bromo-7-[ 11 C]methylpurine for clinical use. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Yitian Wu, Tuo Li, Xianzhong Zhang, Hongli Jing, Fang Li, Li Huo
Preclinical evaluation of the theranostic potential of 89 Zr/ 177 Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Xiaoqun Tang, Shengji Lv, Zhaobiao Mou, Xia Liu, Zijing Li
Cu(II)-Mediated direct 18 F-dehydrofluorination of phosphine oxides in high molar activity. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Alexander Wurzer, Francesco De Rose, Sebastian Fischer, Markus Schwaiger, Wolfgang Weber, Stephan Nekolla, Hans-Jürgen Wester, Matthias Eiber, Calogero D'Alessandria
Preclinical comparison of [ 177 Lu]Lu-rhPSMA-10.1 and [ 177 Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Robert Wodtke, Markus Laube, Sandra Hauser, Sebastian Meister, Friedrich-Alexander Ludwig, Steffen Fischer, Klaus Kopka, Jens Pietzsch, Reik Löser
Preclinical evaluation of an 18 F-labeled N ε -acryloyllysine piperazide for covalent targeting of transglutaminase 2. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Pyry Dillemuth, Tuomas Karskela, Abiodun Ayo, Jesse Ponkamo, Jonne Kunnas, Johan Rajander, Olli Tynninen, Anne Roivainen, Pirjo Laakkonen, Anu J Airaksinen, Xiang-Guo Li
Radiosynthesis, structural identification and in vitro tissue binding study of [ 18 F]FNA-S-ACooP, a novel radiopeptide for targeted PET imaging of fatty acid binding protein 3. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Fabian Krutzek, Cornelius K Donat, Sven Stadlbauer
Chelator impact: investigating the pharmacokinetic behavior of copper-64 labeled PD-L1 radioligands. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
David Alexoff, Seok Rye Choi, Karl Ploessl, Dohyun Kim, Ruiyue Zhao, Lin Zhu, Hank Kung
Optimization and scale up of production of the PSMA imaging agent [ 18 F]AlF-P16-093 on a custom automated radiosynthesis platform. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
T T Cao, E A Aalbersberg, M M Geluk-Jonker, Jeroen J M A Hendrikx
Validation of an automated dispensing system for subsequent dose dispensing of different radionuclides. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Toshimitsu Okamura, Tatsuya Kikuchi, Masanao Ogawa, Ming-Rong Zhang
Improved synthesis of 6-bromo-7-[ 11 C]methylpurine for clinical use. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Lei Wang, Hsiou-Ting Kuo, Zhengxing Zhang, Chengcheng Zhang, Chao-Cheng Chen, Devon Chapple, Ryan Wilson, Nadine Colpo, null François Bénard, Kuo-Shyan Lin
Unnatural amino acid substitutions to improve in vivo stability and tumor uptake of 68 Ga-labeled GRPR-targeted TacBOMB2 derivatives for cancer imaging with positron emission tomography. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Seung Ho Baek, Eun-Ha Hwang, Gyeung Haeng Hur, Green Kim, You Jung An, Jae-Hak Park, Jung Joo Hong
Intranasal administration enhances size-dependent pulmonary phagocytic uptake of poly(lactic-co-glycolic acid) nanoparticles. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Yitian Wu, Tuo Li, Xianzhong Zhang, Hongli Jing, Fang Li, Li Huo
Preclinical evaluation of the theranostic potential of 89 Zr/ 177 Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Ali Fele-Paranj, Babak Saboury, Carlos Uribe, Xinchi Hou
Physiologically based radiopharmacokinetic (PBRPK) modeling to simulate and analyze radiopharmaceutical therapies: studies of non-linearities, multi-bolus injections, and albumin binding. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Santiago Andrés Brühlmann, Martin Walther, Klaus Kopka, Martin Kreller
Production of the PET radionuclide 61 Cu via the 62 Ni(p,2n) 61 Cu nuclear reaction. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Ali Fele-Paranj, Babak Saboury, Carlos Uribe, Xinchi Hou
Physiologically based radiopharmacokinetic (PBRPK) modeling to simulate and analyze radiopharmaceutical therapies: studies of non-linearities, multi-bolus injections, and albumin binding. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Aruna Korde, Marianne Patt, Svetlana V Selivanova, Andrew M Scott, Rolf Hesselmann, Oliver Kiss, Natesan Ramamoorthy, Sergio Todde, Sietske M Rubow, Luther Gwaza, Serge Lyashchenko, Jan Andersson, Brian Hockley, Ravindra Kaslival, Clemens Decristoforo
Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Robert Wodtke, Markus Laube, Sandra Hauser, Sebastian Meister, Friedrich-Alexander Ludwig, Steffen Fischer, Klaus Kopka, Jens Pietzsch, Reik Löser
Preclinical evaluation of an 18 F-labeled N ε -acryloyllysine piperazide for covalent targeting of transglutaminase 2. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Yuta Kaizuka, Hiroyuki Suzuki, Tadashi Watabe, Kazuhiro Ooe, Atsushi Toyoshima, Kazuhiro Takahashi, Koichi Sawada, Takashi Iimori, Yoshitada Masuda, Takashi Uno, Kento Kannaka, Tomoya Uehara
Neopentyl glycol-based radiohalogen-labeled amino acid derivatives for cancer radiotheranostics. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Robert Wodtke, Markus Laube, Sandra Hauser, Sebastian Meister, Friedrich-Alexander Ludwig, Steffen Fischer, Klaus Kopka, Jens Pietzsch, Reik Löser
Preclinical evaluation of an 18 F-labeled N ε -acryloyllysine piperazide for covalent targeting of transglutaminase 2. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
David Alexoff, Seok Rye Choi, Karl Ploessl, Dohyun Kim, Ruiyue Zhao, Lin Zhu, Hank Kung
Optimization and scale up of production of the PSMA imaging agent [ 18 F]AlF-P16-093 on a custom automated radiosynthesis platform. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
David Alexoff, Seok Rye Choi, Karl Ploessl, Dohyun Kim, Ruiyue Zhao, Lin Zhu, Hank Kung
Optimization and scale up of production of the PSMA imaging agent [ 18 F]AlF-P16-093 on a custom automated radiosynthesis platform. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Pyry Dillemuth, Tuomas Karskela, Abiodun Ayo, Jesse Ponkamo, Jonne Kunnas, Johan Rajander, Olli Tynninen, Anne Roivainen, Pirjo Laakkonen, Anu J Airaksinen, Xiang-Guo Li
Radiosynthesis, structural identification and in vitro tissue binding study of [ 18 F]FNA-S-ACooP, a novel radiopeptide for targeted PET imaging of fatty acid binding protein 3. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Fabian Krutzek, Cornelius K Donat, Sven Stadlbauer
Chelator impact: investigating the pharmacokinetic behavior of copper-64 labeled PD-L1 radioligands. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Fabian Krutzek, Cornelius K Donat, Sven Stadlbauer
Chelator impact: investigating the pharmacokinetic behavior of copper-64 labeled PD-L1 radioligands. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Seung Ho Baek, Eun-Ha Hwang, Gyeung Haeng Hur, Green Kim, You Jung An, Jae-Hak Park, Jung Joo Hong
Intranasal administration enhances size-dependent pulmonary phagocytic uptake of poly(lactic-co-glycolic acid) nanoparticles. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Alexander Wurzer, Francesco De Rose, Sebastian Fischer, Markus Schwaiger, Wolfgang Weber, Stephan Nekolla, Hans-Jürgen Wester, Matthias Eiber, Calogero D'Alessandria
Preclinical comparison of [ 177 Lu]Lu-rhPSMA-10.1 and [ 177 Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
T T Cao, E A Aalbersberg, M M Geluk-Jonker, Jeroen J M A Hendrikx
Validation of an automated dispensing system for subsequent dose dispensing of different radionuclides. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
T T Cao, E A Aalbersberg, M M Geluk-Jonker, Jeroen J M A Hendrikx
Validation of an automated dispensing system for subsequent dose dispensing of different radionuclides. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Eline L Hooijman, Valery Radchenko, Sui Wai Ling, Mark Konijnenberg, Tessa Brabander, Stijn L W Koolen, Erik de Blois
Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Seung Ho Baek, Eun-Ha Hwang, Gyeung Haeng Hur, Green Kim, You Jung An, Jae-Hak Park, Jung Joo Hong
Intranasal administration enhances size-dependent pulmonary phagocytic uptake of poly(lactic-co-glycolic acid) nanoparticles. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Lei Wang, Hsiou-Ting Kuo, Zhengxing Zhang, Chengcheng Zhang, Chao-Cheng Chen, Devon Chapple, Ryan Wilson, Nadine Colpo, null François Bénard, Kuo-Shyan Lin
Unnatural amino acid substitutions to improve in vivo stability and tumor uptake of 68 Ga-labeled GRPR-targeted TacBOMB2 derivatives for cancer imaging with positron emission tomography. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Eline L Hooijman, Valery Radchenko, Sui Wai Ling, Mark Konijnenberg, Tessa Brabander, Stijn L W Koolen, Erik de Blois
Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Steve S Huang, Frank P DiFilippo, Daniel J Lindner, Warren D Heston
A novel PSMA-targeting tracer with highly negatively charged linker demonstrates decreased salivary gland uptake in mice compared to [ 68 Ga]Ga-PSMA-11. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Yuta Kaizuka, Hiroyuki Suzuki, Tadashi Watabe, Kazuhiro Ooe, Atsushi Toyoshima, Kazuhiro Takahashi, Koichi Sawada, Takashi Iimori, Yoshitada Masuda, Takashi Uno, Kento Kannaka, Tomoya Uehara
Neopentyl glycol-based radiohalogen-labeled amino acid derivatives for cancer radiotheranostics. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Yitian Wu, Tuo Li, Xianzhong Zhang, Hongli Jing, Fang Li, Li Huo
Preclinical evaluation of the theranostic potential of 89 Zr/ 177 Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer model. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Ali Fele-Paranj, Babak Saboury, Carlos Uribe, Xinchi Hou
Physiologically based radiopharmacokinetic (PBRPK) modeling to simulate and analyze radiopharmaceutical therapies: studies of non-linearities, multi-bolus injections, and albumin binding. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Takayuki Sakai, Aya Ogata, Hiroshi Ikenuma, Takashi Yamada, Saori Hattori, Junichiro Abe, Shinichi Imamura, Masanori Ichise, Mari Tada, Akiyoshi Kakita, Hiroko Koyama, Masaaki Suzuki, Takashi Kato, Kengo Ito, Yasuyuki Kimura
A novel PET probe to selectively image heat shock protein 90α/β isoforms in the brain. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Kristýna Krasulová, Barbora Neuzilova, Katerina Dvorakova Bendova, Zbynek Novy, Miroslav Popper, Marian Hajduch, Milos Petrik
Preclinical characterisation of gallium-68 labeled ferrichrome siderophore stereoisomers for PET imaging applications. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Steve S Huang, Frank P DiFilippo, Daniel J Lindner, Warren D Heston
A novel PSMA-targeting tracer with highly negatively charged linker demonstrates decreased salivary gland uptake in mice compared to [ 68 Ga]Ga-PSMA-11. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Santiago Andrés Brühlmann, Martin Walther, Klaus Kopka, Martin Kreller
Production of the PET radionuclide 61 Cu via the 62 Ni(p,2n) 61 Cu nuclear reaction. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Aruna Korde, Marianne Patt, Svetlana V Selivanova, Andrew M Scott, Rolf Hesselmann, Oliver Kiss, Natesan Ramamoorthy, Sergio Todde, Sietske M Rubow, Luther Gwaza, Serge Lyashchenko, Jan Andersson, Brian Hockley, Ravindra Kaslival, Clemens Decristoforo
Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework. EJNMMI radiopharmacy and chemistry 9 (1) (2024)
Aruna Korde, Marianne Patt, Svetlana V Selivanova, Andrew M Scott, Rolf Hesselmann, Oliver Kiss, Natesan Ramamoorthy, Sergio Todde, Sietske M Rubow, Luther Gwaza, Serge Lyashchenko, Jan Andersson, Brian Hockley, Ravindra Kaslival, Clemens Decristoforo
Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework. EJNMMI radiopharmacy and chemistry 9 (1) (2024)